Advertisement

Rosemary & Carvacrol Nano Emulsions: New Therapy for Melanoma

June, 06, 2024 | Melanoma, Skin Cancer

KEY TAKEAWAYS

  • The study aimed to evaluate the anticancer effects of two plant extract nano emulsions on human melanoma.
  • The results concluded rosemary and carvacrol nano emulsions could revolutionize local human melanoma therapy.

Marwa Mohamed Ahmed Ellithy and the team aimed to evaluate the anticancer effectiveness of 2 plant extract nano emulsions on human melanoma cell lines.

Following synthesis and characterization, carvacrol and rosemary essential oils were skillfully formulated into nano emulsions. These formulations underwent thorough examination using TEM to precisely determine their charge and size distribution. Subsequently, the A375 human melanoma cell line was meticulously cultured and propagated in a controlled environment.

Upon reaching optimal conditions, the IC50 of the prepared nano emulsions was carefully administered to assess their efficacy. Detailed evaluations were conducted to analyze cell cytotoxicity, angiogenesis effects, and apoptosis induction, providing comprehensive insights into their potential therapeutic applications.

The results revealed that both carvacrol nano emulsion (CNE) and rosemary nano emulsion (RNE) inhibited melanoma cell line viability and angiogenesis while enhancing the expression of the caspase-3 proapoptotic marker.

The study concluded that rosemary and carvacrol extract nano emulsions could serve as revolutionary agents in human melanoma therapy, with potential for local application.

No funding information was available.

Source: https://pubmed.ncbi.nlm.nih.gov/38809638/

Ellithy MMA, Abdrabo RAM. (2024). “Plant Based Extract Oil-Based Nano emulsions: Impact on Human Melanoma Cell Line.” Asian Pac J Cancer Prev. 2024 May 1;25(5):1663-1671. doi: 10.31557/APJCP.2024.25.5.1663. PMID: 38809638.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –

Advertisement

LATEST

Advertisement

Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy